Skip to content

SeptiCyte Rapid® as Assessment Tool for Early Recognition of Sepsis

SeptiCyte Rapid® as Assessment Tool for Early Recognition of Sepsis - SeptAsTERS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00024891
Enrollment
200
Registered
2021-04-08
Start date
2021-05-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A41

Interventions

Group 1: Patients with suspected severe infection/sepsis and admission to the intensive care unit will be examined with the SepticyteRapid test within 3 hours after inclusion in the study and in addit

Sponsors

Klinik für Anästhesiologie Universitätsklinikum Heidelberg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age = 18 years - Patients undergoing major elective abdominal surgery. - Initial clinical deterioration with suspected infection and admission to the intensive care unit - Need for blood cultures to be taken as part of standard therapy

Exclusion criteria

Exclusion criteria: - Pregnancy - Inclusion in another interventional study - Prior antibiotic therapy beyond usual perioperative prophylaxis (i.e., >24 h) - Refusal to participate in the study

Design outcomes

Primary

MeasureTime frame
Concordance of SeptiCyte Rapid® results with clinical diagnosis of Sepsis.

Secondary

MeasureTime frame
- Concordance of SeptiCyte Rapid® results with blood cultures taken at the same time (max. +3h) - Comparison of SeptiCyte Rapid® results with other microbiological findings - Comparison of SeptiCyte Rapid® results with routine clinical infection parameters (e.g. PCT, CRP, leukocyte count) - Impact of SeptiCyte Rapid® on diagnostic costs (descriptive analysis)

Countries

Germany

Contacts

Public ContactMaik von der Forst

Klinik für Anästhesiologie Universitätsklinikum Heidelberg

Maik.Forst@med.uni-heidelberg.de06221-56-32939

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026